Billiontoone Inc (BLLN)

Q: What's priced into Billiontoone Inc (BLLN) stock?

BLLN is expensive versus peers, with a reported premium of 1.79 times and a re-rating identified as the main valuation driver. The expectations gap is elevated, but the evidence says the valuation is expensive without the full combination of weak fundamentals and turbulent conditions.

Q: What does the Billiontoone Inc (BLLN) outlook hinge on?

A key near-term test is whether management maintains its reaffirmed guidance, since a cut could lead estimates to be revised lower. Weaker employment data could weigh on cyclical healthcare names, while continued earnings strength and higher guidance from sector bellwethers could support sector momentum.

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23

$107.77+1.98%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Billiontoone Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	121.12M
EPS	—	0.142
FY 2026 · Annual
Revenue	$450M–$465M	454.77M
EPS	—	0.776
FY 2027 · Annual
Revenue	—	573.74M
EPS	—	1.004

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage financial obligations without harming growth	A supporting condition in Billiontoone Inc's published investment case. The stated target is No material financial distress or harmful obligations.	Intact	Material financial obligations impair growth or liquidity	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS improves toward $0.87 in 2026	A supporting condition in Billiontoone Inc's published investment case. The stated target is >= $0.87 per share.	Intact	EPS falls below $0.80 in FY26	Diluted EPS: $0.15 per share FY2026-Q2; GAAP. Published target: >= $0.87 per share. Target period is not explicitly aligned with this observation. Source published Aug 5, 20260.15 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f06f5ef2-87b6-40a9-916e-98466a364c92. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
2026 revenue reaches $450M to $465M	A primary condition in Billiontoone Inc's published investment case. The stated target is >= $450M and <= $465M.	Intact	revenue falls below $450M in FY26	Revenue: $109.448M FY2026-Q2; GAAP. Published target: >= $450M and <= $465M. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026109,448,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f06f5ef2-87b6-40a9-916e-98466a364c92. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue grew from $83.5 million in 2025-Q3 to $108.4 million in 2026-Q1 and $109.4 million in 2026-Q2. Management reiterated 2026 full year revenue guidance at $450 million to $465 million, representing 48% to 52% growth over 2025. The trajectory is delivering consistent revenue growth and guidance upgrades. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.57B

$0.58B → $0.57B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$576,998,650	2 / 8
2026-07-25	Unavailable	$576,998,650	2 / 8
2026-07-26	Unavailable	$576,998,650	2 / 8
2026-07-27	Unavailable	$576,998,650	2 / 8
2026-07-28	Unavailable	$576,998,650	2 / 8
2026-07-29	Unavailable	$576,998,650	2 / 8
2026-07-30	Unavailable	$576,998,650	2 / 8
2026-07-31	Unavailable	$576,998,650	2 / 8
2026-08-01	Unavailable	$577,283,874	4 / 6
2026-08-02	Unavailable	$576,998,650	2 / 8
2026-08-03	Unavailable	$576,998,650	2 / 8
2026-08-04	Unavailable	$576,998,650	2 / 8
2026-08-05	Unavailable	$576,998,650	2 / 8
2026-08-06	Unavailable	$576,998,650	2 / 8
2026-08-07	Unavailable	$578,299,175	3 / 6
2026-08-08	Unavailable	$579,034,260	1 / 8
2026-08-09	Unavailable	$579,034,260	1 / 8
2026-08-10	Unavailable	$579,034,260	1 / 8
2026-08-11	Unavailable	$579,309,260	1 / 8
2026-08-12	Unavailable	$576,121,760	1 / 8
2026-08-13	Unavailable	$576,121,760	1 / 8
2026-08-14	Unavailable	$578,299,175	3 / 6
2026-08-15	Unavailable	$578,299,175	3 / 6
2026-08-16	Unavailable	$578,299,175	3 / 6
2026-08-17	Unavailable	$578,299,175	3 / 6
2026-08-18	Unavailable	$578,299,175	3 / 6
2026-08-19	Unavailable	$578,299,175	3 / 6
2026-08-20	Unavailable	$576,050,000	4 / 6
2026-08-21	Unavailable	$576,050,000	4 / 6
2026-08-22	Unavailable	$576,050,000	4 / 6
2026-08-23	Unavailable	$576,050,000	4 / 6
2026-08-24	Unavailable	$576,050,000	4 / 6
2026-08-25	Unavailable	$576,050,000	4 / 6
2026-08-26	Unavailable	$576,050,000	4 / 6
2026-08-27	Unavailable	$576,050,000	4 / 6
2026-08-28	Unavailable	$576,050,000	4 / 6
2026-08-29	Unavailable	$576,056,951	4 / 6
2026-08-30	Unavailable	$576,056,951	4 / 6
2026-08-31	Unavailable	$576,056,951	4 / 6
2026-09-01	Unavailable	$576,056,951	4 / 6
2026-09-02	Unavailable	$576,056,951	4 / 6
2026-09-03	Unavailable	$576,287,056	4 / 7
2026-09-04	Unavailable	$576,287,056	4 / 7
2026-09-05	Unavailable	$576,287,056	4 / 7
2026-09-06	Unavailable	$576,287,056	4 / 7
2026-09-07	Unavailable	$576,287,056	4 / 7
2026-09-08	Unavailable	$576,287,056	4 / 7
2026-09-09	Unavailable	$576,287,056	4 / 7
2026-09-10	Unavailable	$576,287,056	4 / 7
2026-09-11	Unavailable	$576,287,056	4 / 7
2026-09-12	Unavailable	$576,287,056	4 / 7
2026-09-13	Unavailable	$576,287,056	4 / 7
2026-09-14	Unavailable	$576,287,056	4 / 7
2026-09-15	Unavailable	$576,287,056	4 / 7
2026-09-16	Unavailable	$576,287,056	4 / 7
2026-09-17	Unavailable	$576,287,056	4 / 7
2026-09-18	Unavailable	$576,287,056	4 / 7
2026-09-19	Unavailable	$576,287,056	4 / 7
2026-09-20	Unavailable	$576,287,056	4 / 7
2026-09-21	Unavailable	$576,287,056	4 / 7
2026-09-22	Unavailable	$576,287,056	4 / 7
2026-09-23	Unavailable	$576,287,056	4 / 7
2026-09-24	Unavailable	$576,287,056	4 / 7
2026-09-25	Unavailable	$576,287,056	4 / 7
2026-09-26	Unavailable	$576,287,056	4 / 7
2026-09-27	Unavailable	$576,287,056	4 / 7
2026-09-28	Unavailable	$576,287,056	4 / 7
2026-09-29	Unavailable	$576,287,056	4 / 7
2026-09-30	Unavailable	$576,287,056	4 / 7
2026-10-01	Unavailable	$576,287,056	4 / 6
2026-10-02	Unavailable	$573,672,938	4 / 6
2026-10-03	Unavailable	$573,672,938	4 / 6
2026-10-04	Unavailable	$573,672,938	4 / 6
2026-10-05	Unavailable	$573,672,938	4 / 6
2026-10-06	Unavailable	$573,672,938	4 / 6
2026-10-07	Unavailable	$573,672,938	4 / 6
2026-10-08	Unavailable	$573,672,938	4 / 6
2026-10-09	Unavailable	$573,672,938	4 / 6
2026-10-10	Unavailable	$573,672,938	4 / 6
2026-10-11	Unavailable	$573,672,938	4 / 6
2026-10-12	Unavailable	$573,672,938	4 / 6
2026-10-13	Unavailable	$573,672,938	4 / 6
2026-10-14	Unavailable	$573,672,938	4 / 6
2026-10-15	Unavailable	$573,760,944	4 / 6
2026-10-16	Unavailable	$573,760,944	4 / 6
2026-10-17	Unavailable	$573,760,944	4 / 6
2026-10-18	Unavailable	$573,760,944	4 / 6
2026-10-19	Unavailable	$573,760,944	4 / 6
2026-10-20	Unavailable	$573,744,957	4 / 6
2026-10-21	Unavailable	$573,744,957	4 / 6
2026-10-22	Unavailable	$573,744,957	4 / 6
2026-10-23	Unavailable	$573,744,957	4 / 6
2026-10-24	Unavailable	$573,744,957	4 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	2
2026-06-01	6	2
2026-07-01	6	2
2026-08-01	6	2
2026-09-01	7	2
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

GuggenheimOct 1 · prior Jun 29

$125.00 → $128.00+2.4%

$0$70.40$140.80

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage financial obligations without harming growthQualitative condition
EPS improves toward $0.87 in 2026Diluted EPS: $0.15 per share
2026 revenue reaches $450M to $465MRevenue: $109.448M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-50.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Billiontoone Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-growth healthcare business with improving profitability, rather than a mature, steady compounder. The multi-year view is intact, with stable management and a supportive sector backdrop, but profitability progress is mixed and confidence in the evidence is medium.

What's priced into Billiontoone Inc

BLLN is expensive versus peers, with a reported premium of 1.79 times and a re-rating identified as the main valuation driver. The expectations gap is elevated, but the evidence says the valuation is expensive without the full combination of weak fundamentals and turbulent conditions.

What the fundamentals likely do

Near term, revenue growth and positive operating income support the business setup: management reaffirmed 2026 revenue guidance of $450 million to $465 million, and recent quarterly revenue rose to $109.4 million. Operating income remains positive, though it fell from $17.8 million in 2026-Q1 to $5.5 million in 2026-Q2; product launches add potential, but their financial impact is not yet quantified.

What Billiontoone Inc hinges on